CIK 0001585608
- Non-accelerated filer
- Smaller reporting company
Jaguar Health, Inc.
Sign in to watch- Ticker
- JAGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 415-371-8300
- Business address
- 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
- Former names
- Jaguar Animal Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-24 | Siegel Jonathan B. Director | Grant or award · Warrant to Purchase Common Stock | +18,262 | 9,000 | ||
| 2025-06-24 | MICEK JOHN Director | Returned to the company · Convertible Promissory Note | −9,000 | $50,000.00 | $450.0M | 0 |
| 2025-06-24 | MICEK JOHN Director | Grant or award · Convertible Promissory Note | +9,462 | $50,000.00 | $473.1M | 9,462 |
| 2025-06-24 | MICEK JOHN Director | Grant or award · Warrant to Purchase Common Stock | +18,262 | 9,000 | ||
| 2025-06-24 | BOCHNOWSKI JAMES J Director | Returned to the company · Convertible Promissory Note | −27,002 | $150,000.00 | $4.1B | 0 |
| 2025-06-24 | BOCHNOWSKI JAMES J Director | Grant or award · Convertible Promissory Note | +28,388 | $150,000.00 | $4.3B | 28,388 |
| 2025-06-24 | BOCHNOWSKI JAMES J Director | Grant or award · Warrant to Purchase Common Stock | +54,786 | 27,002 | ||
| 2025-06-24 | King Steven R. See Remarks | Returned to the company · Convertible Promissory Note | −3,600 | $20,000.00 | $72.0M | 0 |
| 2025-06-24 | King Steven R. See Remarks | Grant or award · Convertible Promissory Note | +3,785 | $20.00 | $76K | 3,785 |
| 2025-06-24 | King Steven R. See Remarks | Grant or award · Warrant to Purchase Common Stock | +7,304 | 3,600 | ||
| 2025-06-24 | Chaturvedi Pravin R Chief Scientific Officer | Returned to the company · Convertible Promissory Note | −3,600 | $20,000.00 | $72.0M | 0 |
| 2025-06-24 | Chaturvedi Pravin R Chief Scientific Officer | Grant or award · Convertible Promissory Note | +3,785 | $20,000.00 | $75.7M | 3,785 |
| 2025-06-24 | Chaturvedi Pravin R Chief Scientific Officer | Grant or award · Warrant to Purchase Common Stock | +7,304 | 3,600 | ||
| 2025-06-24 | Wolin Jonathan S. See Remarks | Returned to the company · Convertible Promissory Note | −9,000 | $50,000.00 | $450.0M | 0 |
| 2025-06-24 | Wolin Jonathan S. See Remarks | Grant or award · Convertible Promissory Note | +9,462 | $50,000.00 | $473.1M | 9,462 |
| 2025-06-24 | Wolin Jonathan S. See Remarks | Grant or award · Warrant to Purchase Common Stock | +18,262 | 9,000 | ||
| 2025-06-24 | CONTE LISA A CEO and President | Returned to the company · Convertible Promissory Note | −9,000 | $50,000.00 | $450.0M | 0 |
| 2025-06-24 | CONTE LISA A CEO and President | Grant or award · Convertible Promissory Note | +9,462 | $50,000.00 | $473.1M | 9,462 |
| 2025-06-24 | CONTE LISA A CEO and President | Grant or award · Warrant to Purchase Common Stock | +18,262 | 9,000 | ||
| 2025-05-17 | King Steven R. See Remarks | Option exercise | +1 | 145 |
Page 2 of 10 · 185 trades